Welcome to our dedicated page for Emergent Health news (Ticker: EMGE), a resource for investors and traders seeking the latest updates and insights on Emergent Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Emergent Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Emergent Health's position in the market.
Emergent Health Corp. (OTC PINK:EMGE) announced a partnership between its subsidiary PharmaZu and DynaCord, LLC for the co-development and exclusive marketing of injectable and topical biologic Exosomes aimed at treating arthritis, joint care, and inflammation in pets. The demand for Exosomes is rising, with the human market projected to achieve a CAGR of 27.89% until 2026. The pet industry saw a 54% increase in dog ownership in 2020, with forecasts suggesting spending may exceed $275 billion by 2030. This agreement aims to deliver innovative therapies to the pet market.
Emergent Health Corp. (OTC PINK:EMGE) announced that Chief Marketing Officer Marvin Segel, son of QVC founder Joseph Segel, will appear on the Digital Stock & Investment News Network Rich TV Live today at 1 PM ET. During the interview, Segel will share insights about his background, the company's status, his role, and strategic goals for the upcoming year. Rich TV Live aims to provide in-depth company information to investors through various social media platforms.
Emergent Health Corp. (OTC PINK:EMGE) announced that its Chief Marketing Officer, Marvin Segel, will appear on Rich TV Live today at 1 PM ET. The discussion will cover Segel's background, business achievements, and Emergent's current status and future goals over the next year. The interview will be accessible on Emergent's social media platforms after airing. Emergent develops health technologies and nutraceuticals, including products like Vita-Stim and Neuvitale, which are distributed through various retail outlets.
Emergent Health Corp. (OTC PINK:EMGE) has appointed Marvin Segel, son of QVC's founder, as Director and Chief Marketing Officer. With over 20 years in direct-to-consumer marketing, Segel aims to enhance the company's Health & Wellness products. He previously held significant roles at The Y Networks and ShopNBC, where he generated millions in revenue. CEO James Zimbler highlighted Segel's extensive experience and network as key assets for market success. Emergent offers regenerative medicine and nutraceuticals, distributing through various channels.
Emergent Health Corp. (OTC PINK:EMGE) has appointed James Zimbler as its new CEO, replacing Frank Magliochetti, who will remain as a consultant. Zimbler brings extensive experience in bio-wellness and pet wellness industries, having previously held key positions at Cannagistics and Enzolytics. He aims to expand Emergent's presence in the nutritional supplement and pet pharmacy markets, leveraging his experience to enhance sales channels. The company continues to focus on regenerative medicine and nutraceuticals, although none of its products are FDA-approved for treating diseases.
Emergent Health Corp. (OTC PINK: EMGE) announced the passing of Dr. John V. Cappello, the company's President and Founder, on February 8, 2022. The Board of Directors expressed deep condolences and reaffirmed confidence in the management team to carry on Dr. Cappello's vision for the company’s nutritional supplement and product development. Emergent Health focuses on natural stem cell mobilizing agents and diet aids, including its newly acquired subsidiary, PharmaZu, which specializes in pet wellness. The company does not claim FDA approval for its products.
Emergent Health Corp. (OTC PINK:EMGE) is entering the $60 billion global anti-aging market with its new product, Infinity Plus Multi™, aimed at supporting adult stem cell health, telomere integrity, and providing specialized anti-aging antioxidants. The product is set for delivery next month, priced at $49.99, which management believes is competitive. The anti-aging market is projected to grow at a CAGR of 5.3% from $42.46 billion in 2020 to $60.95 billion by 2027. Despite the product's innovative features, the company warns of risks related to market competition and financial sustainability.
Emergent Health Corp. (OTC PINK:EMGE) has acquired PharmaZu Corp., an e-commerce provider focused on the pet pharmacy and wellness sectors. This acquisition is timely as the global veterinary medicine market is forecasted to grow from USD 30.8 billion in 2021 to USD 50.8 billion by 2028, with a CAGR of 7.4%.
PharmaZu aims to capitalize on rising demand for OTC pet medications as pet owners increasingly prioritize health. The acquisition aligns with Emergent's strategy to penetrate this expanding market and enhance its portfolio.